FINWIRES · TerminalLIVE
FINWIRES
Novo Nordisk

Novo Nordisk

$NVO
NYSEPharmaceuticals

93 stories mentioning Novo NordiskUpdated 6d ago

A drugmaker in focus as CMS proposed a permanent Medicare drug-price-negotiation framework from 2029, while healthcare stocks rose.

Sectors

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks were higher late Wednesday afternoon, with the NYSE Health Care Index increasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.2%.The iShares Biotechnology ETF (IBB) climbed up 2.1%.In corporate news, Oscar Health (OSCR) shares surged past 10% after the company reported higher Q1 results.DaVita (DVA) shares jumped past 22% after Deutsche Bank upgraded the stock to buy from hold and boosted its price target to $220 from $126, a day after the company reported better-than-expected Q1 results.CVS Health (CVS) raised its full-year earnings outlook after reporting better-than-expected Q1 results on improvement in its health-care benefits segment. Its shares gained 8%.Novo Nordisk (NVO) expects generic versions of its Ozempic medication to face approval delays in China until next year, Bloomberg reported, citing the drugmaker. The patent for semaglutide, the main ingredient in Ozempic and Wegovy, expired in China in March, but the firm said it still has regulatory data protection until April 2027 due to a trade agreement between China and Switzerland, Bloomberg reported. Novo shares rose 2.2%.

$CVS$DVA$NVO$OSCR
Sectors

Sector Update: Health Care Stocks Mixed Wednesday Afternoon

Health care stocks were mixed Wednesday afternoon, with the NYSE Health Care Index increasing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.1%.The iShares Biotechnology ETF (IBB) climbed 1.8%.In corporate news, CVS Health (CVS) raised its full-year earnings outlook after reporting better-than-expected Q1 results driven by improvement in its health-care benefits segment. Its shares gained 6.8%.Novo Nordisk (NVO) expects generic versions of its Ozempic medication to face approval delays in China until next year, Bloomberg reported, citing the drugmaker. The patent for semaglutide, the main ingredient in Ozempic and Wegovy, expired in China in March, but the company said it still has regulatory data protection until April 2027 due to a trade agreement between China and Switzerland, Bloomberg reported. Novo shares rose 2.5%.Eli Lilly (LLY) is looking to raise about $8 billion from an investment-grade bond sale to fund an acquisition spree, Bloomberg reported. Lilly shares added 0.3%.

$CVS$LLY$NVO
Wire

Market Chatter: Novo Nordisk Expects Delay for Generic Ozempic in China

Novo Nordisk (NVO) expects generic versions of its Ozempic medication to face approval delays in China until next year, Bloomberg News reported Wednesday, citing the drugmaker.The patent for semaglutide, the main ingredient in Ozempic and Wegovy, expired in China in March, but the company said it still has regulatory data protection until April 2027 due to a trade agreement between China and Switzerland, Bloomberg reported.Hangzhou Jiuyuan Genetic Biopharmaceutical, the first Chinese firm to seek clearance for a generic, said in March its product review was suspended because of the international data protection stipulations, according to the report.Novo Nordisk and Hangzhou Jiuyuan did not immediately respond to' requests for comment, while the Chinese regulatory authority could not be reached for comment.Novo Nordisk shares were more than 3% higher in Wednesday trading.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $46.21, Change: $+1.34, Percent Change: +2.98%

$NVO
Sectors

Sector Update: Health Care Stocks Gain Pre-Bell Wednesday

Health care stocks were higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) gaining by 0.1% and the iShares Biotechnology ETF (IBB) advancing 1%.Novo Nordisk (NVO) stock was up more than 6% premarket after the company posted higher-than-expected Q1 earnings and revenue in addition to raising its 2026 adjusted sales growth guidance.Royal Philips (PHG) shares were up more than 1% pre-bell after the company reported higher-than-expected Q1 adjusted income from continuing operations and revenue.Oscar Health (OSCR) stock was up over 9% premarket after the company reported higher Q1 adjusted earnings and revenue.

$IBB$NVO$OSCR$PHG$XLV
Sectors

Sector Update: Health Care

Health care stocks were edging higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) gaining by 0.1% and the iShares Biotechnology ETF (IBB) advancing 1%.Novo Nordisk (NVO) stock was up more than 6% premarket after the company posted higher-than-expected Q1 earnings and revenue in addition to raising its 2026 adjusted sales growth guidance.

$IBB$NVO$XLV
Commodities

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Potential US-Iran Truce

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 1% and the actively traded Invesco QQQ Trust (QQQ) was 1.7% higher in Wednesday's premarket activity amid news of a potential US-Iran truce.US stock futures were mixed, with S&P 500 Index futures up 1%, Dow Jones Industrial Average futures falling 1.2%, and Nasdaq futures advancing 1.6% before the start of regular trading.US mortgage applications fell in the week ended May 1 amid higher mortgage rates, according to data released by the Mortgage Bankers Association early Wednesday.ADP's monthly measure of private payrolls showed a 109,000 increase in April, below expectations compiled by Bloomberg as of 7:20 am ET for an increase of 120,000.State-level unemployment data for March is slated for a 10 am ET release, followed by the weekly petroleum stocks at 10:30 am ET.Chicago Federal Reserve President Austan Goolsbee is due to speak on Wednesday.In premarket activity, bitcoin was down by 1.3%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 1.3% higher, Ether ETF (EETH) advanced 2%, and Bitcoin & Ether Market Cap Weight ETF (BETH) fell over 14%.Power Play:FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.6%. Direxion Daily Financial Bull 3X Shares (FAS) was up 2%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 1.9% lower.Hut 8 (HUT) shares were up more than 24% pre-bell after the company reported higher Q1 revenue.Winners and Losers:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) gained 2.1%, and the iShares US Technology ETF (IYW) was 2.4% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 2.3%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) rose 3.6%, while the iShares Semiconductor ETF (SOXX) increased by 4.3%.Advanced Micro Devices (AMD) shares were up more than 18% in premarket activity after the company overnight posted stronger-than-expected fiscal Q1 results and issued an upbeat Q2 revenue outlook.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.1%, the Vanguard Health Care Index Fund (VHT) was up 0.3%, while the iShares US Healthcare ETF (IYH) was flat. The iShares Biotechnology ETF (IBB) was 1% higher.Novo Nordisk (NVO) stock was up more than 6% premarket after the company posted higher-than-expected Q1 earnings and revenue in addition to raising its 2026 adjusted sales growth guidance.EnergyThe iShares US Energy ETF (IYE) was down 4.2%, while the State Street Energy Select Sector SPDR ETF (XLE) fell by 4.8%.Equinor (EQNR) stock was down more than 9% before Wednesday's opening bell after the company reported lower Q1 revenue.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 1.8%, while the Vanguard Industrials Index Fund (VIS) was up 2.3%, and the iShares US Industrials ETF (IYJ) was inactive.Ametek (AME) stock was up more than 2% before the opening bell after the company agreed to acquire Indicor Instrumentation from Indicor in an all-cash deal valued at about $5 billion.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.4%, and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was up 0.2%. The iShares US Consumer Staples ETF (IYK) was flat. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) gained 1.3%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was 1.2% lower.Amazon (AMZN) shares were up more than 1% a day after The Information reported the company-backed Anthropic will pay Alphabet's (GOOG, GOOGL) Google Cloud about $200 billion over five years for computing capacity and processors.CommoditiesFront-month US West Texas Intermediate crude oil retreated by 10% to $91.80 per barrel on the New York Mercantile Exchange. Natural gas was down by 2.5% at $2.72 per 1 million British Thermal Units. The United States Oil Fund (USO) fell by 9.6%, while the United States Natural Gas Fund (UNG) was 1.6% lower.Gold futures for May rose by 3.1% to $4,711.90 an ounce on the Comex. Silver futures advanced by 5.7% to $77.79 an ounce. SPDR Gold Shares (GLD) was 3% higher, and the iShares Silver Trust (SLV) rose by 5.4%.

Dow JonesNasdaq CompositeS&P 500$AMD$AME$AMZN$BETH$BITO$EEM$EETH$EQNR$EXI$FAS$FAZ$GLD$GOOG$GOOGL$HUT$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$NVO$PMR$QQQ$RTH$SLV$SOXX$SPY$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
US Markets

Stocks Rise Pre-Bell, Oil Prices Fall After Report Says US, Iran Nearing Peace Agreement

The main US stock measures were pointing higher in Wednesday's premarket activity, while oil prices declined after a media report said the US and Iran are nearing a potential agreement to end their conflict.The S&P 500 and the Dow Jones Industrial Average rose 0.7% each before the opening bell, while the Nasdaq advanced 1.2%. The indexes finished the previous trading session in the green, with the S&P 500 and the Nasdaq closing with new highs.Washington is nearing an agreement with Tehran on a one-page memorandum of understanding to end their conflict in the Middle East and establish a framework for more detailed nuclear negotiations, Axios reported Wednesday, citing two US officials and two other sources familiar with the matter.In a social media post on Tuesday, President Donald Trump said the US is temporarily pausing "Project Freedom," its effort to guide neutral ships locked up in the Strait of Hormuz out of the crucial waterway. Trump noted that the US blockade on Iranian ports will remain in effect.US Defense Secretary Pete Hegseth reportedly said Tuesday that the ceasefire agreement with Iran remained intact despite recently renewed tensions in the Gulf region.West Texas Intermediate crude oil dropped 9.3% to $92.88 a barrel in premarket action, while Brent fell 8.3% to $100.77.Treasury yields slipped before the open, with the two-year rate retreating 7.3 basis points to 3.87% and the 10-year rate off 6.8 basis points to 4.35%.Walt Disney (DIS), Uber Technologies (UBER), CVS Health (CVS), Marriott International (MAR), Johnson Controls International (JCI), Restaurant Brands International (QSR), Kraft Heinz (KHC) and Performance Food Group (PFGC) are some of the major companies scheduled to report their latest financial results before the bell, among others.Arm Holdings (ARM), Applovin (APP), DoorDash (DASH) and Warner Bros. Discovery (WBD) post earnings after the markets close.Shares of Advanced Micro Devices (AMD) jumped 18% pre-bell after the chipmaker reported stronger-than-expected first-quarter results. Novo Nordisk's (NVO) US-listed stock climbed 7.5% as the Danish pharmaceutical giant issued an improved full-year sales outlook. Arista Networks (ANET) declined 8.1% after it issued a downbeat second-quarter revenue outlook.Wednesday's economic calendar has the weekly mortgage applications bulletin at 7 am ET, followed by the ADP Employment report for April at 8:15 am. The weekly EIA domestic petroleum inventories report is out at 10:30 am.Federal Reserve Bank of St. Louis President Alberto Musalem is slated to speak at 9:30 am, while Chicago Fed President Austan Goolsbee speaks at 1 pm.Gold increased 3.1% to $4,710 per troy ounce, while bitcoin moved up 0.8% to $82,210.

Dow JonesNasdaq CompositeS&P 500$AMD$ANET$APP$ARM$CVS$DASH$DIS$JCI$KHC$MAR$NVO$PFGC$QSR$UBER$WBD
Research

Research Alert: Novo Nordisk Raises 2026 Outlook On Strong Wegovy Pill Sales

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Reported Q1 sales and operating profit surged 24% and 54%, respectively, boosted by a $4.2B reversal of 340B Drug Pricing Program rebate provision. On an adjusted basis (excluding this item), sales declined 10% (or -4% CER) due to lower realized prices, particularly in the U.S., partially offset by volume growth. The Wegovy pill, launched in January, delivered DKK2.3B in Q1 sales with weekly prescriptions exceeding 200k by mid-April and 2M+ total prescriptions, while injectable Wegovy grew 12% CER internationally, though U.S. sales fell 11% CER on pricing pressure. Management raised its 2026 outlook, with adjusted sales and operating profit now expected to decline 4%-12% CER (vs. prior -5% to -13%), reflecting stronger GLP-1 expectations, particularly for the Wegovy pill. Wegovy pill's strong launch trajectory is encouraging, with international rollout expected in 2H 2026. However, persistent U.S. pricing pressure, mixed clinical data (CagriSema setbacks), and intensifying competition warrant close monitoring.

$NVO
Sectors

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Friday afternoon with the NYSE Health Care Index easing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 0.4%.The iShares Biotechnology ETF (IBB) shed 0.6%.In corporate news, Moderna (MRNA) affirmed its 2026 revenue growth outlook and reported better-than-expected Q1 results amid higher COVID vaccine sales. The stock still declined 1.4%.Amgen's (AMGN) Q1 EPS beat was primarily driven by lower administrative costs and taxes, Morgan Stanley said. Amgen shares fell 4.9%.Eli Lilly's (LLY) international rollout of its new oral weight-loss drug is off to a strong start, with early demand for Foundayo building quickly, BofA Securities said. Lilly shares rose 3.1%.Novo Nordisk (NVO) rebranded its oral semaglutide medication for type 2 diabetes as Ozempic. It was formerly marketed as Rybelsus. Novo shares gained 3.9%.

$AMGN$LLY$MRNA$NVO
Sectors

Sector Update: Health Care Stocks Softer Friday Afternoon

Health care stocks fell Friday afternoon with the NYSE Health Care Index easing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) shed 0.7%.In corporate news, Moderna (MRNA) affirmed its 2026 revenue growth outlook and reported better-than-expected Q1 results amid higher COVID vaccine sales. The stock still declined 2.9%.Amgen's (AMGN) Q1 EPS beat was primarily driven by lower administrative costs and taxes, Morgan Stanley said. Amgen shares fell 5.6%.Novo Nordisk (NVO) rebranded its oral semaglutide medication for type 2 diabetes as Ozempic. It was formerly marketed as Rybelsus. Novo shares gained 3.2%.

$AMGN$MRNA$NVO
Asia Markets

European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for Week

European equities traded in the US as American depositary receipts were trending marginally higher late Friday morning, rising 0.05% to 1,824.45 on the S&P Europe Select ADR Index, which is up 1.25% for the week so far.From continental Europe, the gainers were led by telecommunications company Nokia (NOK) and pharmaceutical company Novo Nordisk (NVO), which climbed 6.3% and 3.6% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and consumer goods company Unilever (UL), which advanced 3.3% and 3% respectively.The decliners from continental Europe were led by biotech firm BioNTech (BNTX) and furniture maker Natuzzi (NTZ), which dropped 6% and 3.5% respectively. They were followed by biopharmaceutical company DBV Technologies (DBVT) and petroleum refiner Equinor (EQNR), which lost 3.3% and 2.4% respectively.The gainers from the UK were led by educational publisher Pearson (PSO) and biopharmaceutical company Akari Therapeutics (AKTX), which rose 3.2% and 2.8% respectively. They were followed by biopharmaceutical company Bicycle Therapeutics (BCYC) and cruise line operator Carnival (CUK), which were up 2.7% and 2.5% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Amarin (AMRN) and oil and gas company BP (BP), which fell 2.8% and 1.9% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and oil and gas company Shell (SHEL), which were down 1.4% and 1.2% respectively.

$AKTX$AMRN$BCYC$BDRX$BNTX$BP$CLLS$CUK$DBVT$EQNR$NOK$NTZ$NVO$PSO$SHEL$UL
Sectors

Sector Update: Health Care Stocks Advance Pre-Bell Friday

Health care stocks were advancing pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.2% higher and the iShares Biotechnology ETF (IBB) up 0.2%.Novo Nordisk (NVO) shares were up more than 2% after the company said it has rebranded its oral semaglutide medication for type 2 diabetes, formerly known as Rybelsus, as Ozempic.Veeva Systems (VEEV) is set to join the S&P 500 on May 7, to replace Coterra Energy (CTRA), S&P Dow Jones Indices said. Shares of Veeva Systems were up more than 11% premarket.Moderna (MRNA) stock was up more than 2% after the company reported a narrower-than-expected Q1 net loss.

$CTRA$IBB$MRNA$NVO$VEEV$XLV
Sectors

Sector Update: Health Care

Health care stocks were advancing pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.3% higher and the iShares Biotechnology ETF (IBB) up 0.2%.Novo Nordisk (NVO) shares were up more than 2% after the company said it has rebranded its oral semaglutide medication for type 2 diabetes, formerly known as Rybelsus, as Ozempic.

$NVO
Sectors

Sector Update: Health Care Stocks Gain Late Afternoon

Health care stocks rose late Thursday afternoon with the NYSE Health Care Index climbing 2.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.3%.The iShares Biotechnology ETF (IBB) advanced 1.9%.In corporate news, UniQure (QURE) shares jumped past 16% after the company said it plans to submit a UK marketing authorization application in Q3 for AMT-130 to treat Huntington's disease.Axsome Therapeutics (AXSM) shares surged 12% after it said the US Food and Drug Administration approved Auvelity to treat agitation associated with Alzheimer's disease dementia.Eli Lilly (LLY) raised its full-year outlook and reported Q1 results above market estimates as sales of Mounjaro more than doubled. Lilly shares jumped past 10%.The US Food and Drug Administration is proposing to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances. Eli Lilly makes tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Novo Nordisk (NVO) makes semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management. Novo shares rose past 5%.

$AXSM$LLY$NVO$QURE
Sectors

Sector Update: Health Care Stocks Gain Thursday Afternoon

Health care stocks rose Thursday afternoon with the NYSE Health Care Index climbing 2.5% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.3%.The iShares Biotechnology ETF (IBB) advanced 2%.In corporate news, Eli Lilly (LLY) raised its full-year outlook and reported Q1 results above market estimates as sales of Mounjaro more than doubled. Lilly shares jumped 10%.The US Food and Drug Administration is proposing to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances. Eli Lilly makes tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Novo Nordisk (NVO) makes semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management. Novo shares rose 5.0%.NovoCure (NVCR) shares surged 28% after the company posted Q1 results.

$LLY$NVCR$NVO
Wire

Update: FDA Seeks to Exclude Tirzepatide, Semaglutide, Liraglutide From 503B Bulks List

(Updates with Lilly's comment in the third paragraph.)The US Food and Drug Administration said Thursday it is proposing to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances.Eli Lilly (LLY) manufactures tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Novo Nordisk (NVO) manufactures semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management.In an emailed statement to, Lilly said it is "pleased FDA has confirmed there is no clinical need for compounded tirzepatide. That means there is no basis for compounders to make tirzepatide knockoffs. Lilly will continue working to protect patients from the risks associated with unapproved drugs prescribed without a medical need."Under federal law, outsourcing facilities generally cannot compound drugs from bulk substances unless the ingredient appears on the 503B bulks list or the compounded drug is on the FDA's drug-shortage list at the time of compounding, distribution and dispensing, the agency said.The FDA is accepting public comments on the proposal through June 29.Novo Nordisk didn't immediately reply to a request for comment from.Lilly shares jumped 9.8% in Thursday trading, and Novo Nordisk gained 5.7%Price: $934.57, Change: $+83.36, Percent Change: +9.79%

$LLY$NVO
Asia Markets

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

European equities traded in the US as American depositary receipts rose late Thursday morning, gaining 2.20% to 1,818.51 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by pharmaceutical company Novo Nordisk (NVO) and lender ING Groep (ING), which advanced 5.3% and 4.9% respectively. They were followed by biopharmaceutical firm Grifols (GRFS) and consumer goods firm Unilever (UL), which rose 3.2% and 3.1% respectively.The decliners from continental Europe were led by internet advertising firm Criteo (CRTO) and telecommunications company Nokia (NOK), which fell 3.2% and 1.9% respectively.The gainers from the UK were led by cruise line operator Carnival (CUK) and utilities company National Grid (NGG), which rose 4.8% and 3.5% respectively. They were followed by Lloyds Banking Group (LYG) and telecommunications operator Vodafone Group (VOD), which were up 2.6% and 2.3% respectively.The decliners from the UK and Ireland were led by software firm Endava (DAVA) and Bicycle Therapeutics (BCYC), which lost 5.2% and 2.3% respectively. They were followed by biopharmaceutical companies Amarin (AMRN) and Mereo BioPharma Group (MREO), which fell 1.3% and 0.9% respectively.

$AMRN$BCYC$CRTO$CUK$DAVA$GRFS$ING$LYG$MREO$NGG$NOK$NVO$UL$VOD
Wire

FDA Proposes to Exclude Semaglutide, Tirzepatide, Liraglutide From 503B Bulks List

The US Food and Drug Administration said Thursday it is proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances.Novo Nordisk (NVO) manufactures semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management. Eli Lilly (LLY) manufactures tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.Normally, outsourcing facilities cannot compound drugs using bulk drug substances unless the substance is on the 503B bulks list or the compounded drug is on the FDA's drug shortage list at the time of compounding, distribution, and dispensing, the FDA said.Novo Nordisk and Eli Lilly didn't immediately reply to requests for comment from.Price: $42.48, Change: $+2.19, Percent Change: +5.44%

$LLY$NVO
Wire

FDA Proposes to Exclude Semaglutide, Tirzepatide, Liraglutide From 503B Bulks List

FDA Proposes to Exclude Semaglutide, Tirzepatide, Liraglutide From 503B Bulks List

$LLY$NVO
Asia Markets

European Equities Traded in the US as American Depositary Receipts Decline Tuesday

European equities traded in the US as American depositary receipts were lower on Tuesday morning, down 0.3% to 1,784.71 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by technology company Opera (OPRA) and telecoms, information technology, and consumer electronics corporation Nokia (NOK), which climbed 7.8% and 1.4% respectively.They were followed by pharmaceutical giant Novo Nordisk (NVO), which added 1%.The decliners from continental Europe were led by semiconductor companies Sequans Communications (SQNS) and ASML (ASML), which fell 6.2% and 4.7% respectively.They were followed by solar energy technology company Turbo Energy (TURB), which shed 3.7%.From the UK and Ireland, the gainers were led by clinical-stage biopharmaceutical company Autolus Therapeutics (AUTL), which rose 3.2%, followed by oil and gas companies Shell (SHEL) and BP (BP), which advanced 1.3% and 1.1% respectively.The decliners from the UK and Ireland were led by semiconductor company Arm (ARM) and budget airline Ryanair (RYAAY), which dropped 8.9% and 2.4% respectively.

$ARM$ASML$AUTL$BP$NOK$NVO$OPRA$RYAAY$SHEL$SQNS$TURB

Showing 61-80 of 93

Track with the FINWIRES app suite

FolioX
FolioX
Track Novo Nordisk in your portfolio
WheelAI
WheelAI
Analyze Novo Nordisk options with the wheel strategy
StockInsider
StockInsider
See market sentiment on Novo Nordisk